Merck & Company Inc (MRK)vsPro-Dex Inc (PDEX)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
PDEX
Pro-Dex Inc
$67.00
+2.81%
HEALTHCARE · Cap: $207.53M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 88017% more annual revenue ($65.77B vs $74.64M). PDEX leads profitability with a 16.1% profit margin vs 13.6%. PDEX trades at a lower P/E of 17.9x. PDEX earns a higher WallStSmart Score of 57/100 (C).
MRK
Hold50
out of 100
Grade: D+
PDEX
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for PDEX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Safe zone — low bankruptcy risk
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Earnings expanding 22.4% YoY
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PDEX
The strongest argument for PDEX centers on Altman Z-Score, Return on Equity, P/E Ratio. Profitability is solid with margins at 16.1% and operating margin at 15.5%. Revenue growth of 14.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PDEX
The primary concerns for PDEX are Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while PDEX is a mature play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
PDEX is growing revenue faster at 14.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PDEX scores higher overall (57/100 vs 50/100), backed by strong 16.1% margins and 14.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Pro-Dex Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?